Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Available 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Neuroblastoma 6Sarcoma, Ewing 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioma 2Glioblastoma 2Astrocytoma 2Typical Teratoid Rhabdoid Tumor 1Rhabdoid Tumor 1Prostatic Neoplasms 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 6Vincristine 3Temozolomide 3Radiotherapy 3Cisplatin 3Automobiles 3fludarabine 2Etoposide 2Eflornithine 2Carboplatin 2omburtamab I-131 1ibrutinib 1gallium Ga 68 dotatate 1etoposide phosphate 1belzutifan 1Zoledronic Acid 1Thiotepa 1Tamoxifen 1Standard of Care 1Radiotherapy, Image-Guided 1Pemetrexed 1ONC206 1Nivolumab 1Mesna 1Maintenance Chemotherapy 1Lomustine 1Isotretinoin 1Induction Chemotherapy 1Hydrocortisone 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Eflornithine × 1 year × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT03581240 2026-02-20

An Intermediate Expanded Use Trial of DFMO

Milton S. Hershey Medical Center

Available
CNS

Typical Teratoid Rhabdoid Tumor, Medulloblastoma, Neuroblastoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡